Patents Issued in December 14, 2021
-
Patent number: 11197822Abstract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.Type: GrantFiled: March 11, 2019Date of Patent: December 14, 2021Assignees: The Regents of the University of California, Meritage Pharma, Inc.Inventors: Ranjan Dohil, John Bastian, Seema Aceves, Elaine Phillips, Malcolm Hill
-
Patent number: 11197823Abstract: Provided herein is an oral liquid suspension that includes topiramate, as well as methods of medical treatment that include orally administering the oral liquid suspension.Type: GrantFiled: November 18, 2020Date of Patent: December 14, 2021Inventors: Paul Sudhakar, Scott Boyer
-
Patent number: 11197824Abstract: A method of reducing the virulence of microbes in or on the human body and a method of sanitizing or disinfecting a surface, area, object, or porous or non porous material is provided. The methods comprise applying or injecting a solution having an effective amount of a conjugated diene for substantially reducing the virulence of the microbes or sanitizing or disinfecting a surface, area, object, or porous or non porous material.Type: GrantFiled: July 24, 2020Date of Patent: December 14, 2021Inventors: David G. Changaris, Anne L. Carenbauer
-
Patent number: 11197825Abstract: Provided herein is an oral liquid suspension that includes topiramate, as well as methods of medical treatment that include orally administering the oral liquid suspension.Type: GrantFiled: June 8, 2020Date of Patent: December 14, 2021Inventors: Paul Sudhakar, Scott Boyer
-
Patent number: 11197826Abstract: Retinoic acid, or an analogue thereof, is delivered within an oil-in-water emulsion to provide an improved immunological adjuvant.Type: GrantFiled: December 21, 2016Date of Patent: December 14, 2021Assignee: NOVARTIS AGInventors: Ugo D'Oro, Luis Brito, Derek O'Hagan, Silvia Vendetti
-
Patent number: 11197827Abstract: Polynucleotides such as DNA are stored inside vesicles formed from self-assembling membranes. The vesicles may be protocells, liposomes, micelles, colloidosomes, proteinosomes, or coacervates. The vesicles may include surface functionalization to improve polynucleotide encapsulation and/or to bind polynucleotides having specific sequences. Encapsulation in vesicles provides protection for the polynucleotides. Additional protection is provided by addition of one or more stabilizers. The stabilizer may be nucleic-acid stabilizers that stabilize the polynucleotides or may be a protective structural layer around the vesicles such as a layer of silica. A process for stably storing polynucleotides in vesicles and a process for recovering stored polynucleotides from vesicles are both disclosed. The polynucleotides may be used for storage of digital information.Type: GrantFiled: October 31, 2018Date of Patent: December 14, 2021Assignee: MICROSOFT TECHNOLOGY LICENSING, LLCInventors: Karin Strauss, Bichlien Hoang Nguyen
-
Patent number: 11197828Abstract: The present invention relates to a pharmaceutical composition comprising compound having a log P of at least 5 and a vehicle, wherein the vehicle comprises (a) a fat component in an amount sufficient to achieve lymphatic absorption in a mammal, wherein the fat component is selected from a mono-glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids.Type: GrantFiled: June 17, 2015Date of Patent: December 14, 2021Assignee: SOLURAL PHARMA APSInventor: Bent Højgaard
-
Patent number: 11197829Abstract: The present invention relates to a technical field of pharmaceutical preparation, in particular to a preparation method of naltrexone implants, including the following steps: (1) dissolving naltrexone and polylactic acid in an organic solvent to form naltrexone microspheres, and drying; (2) placing the naltrexone microspheres in a heated tableting mold for tableting, and obtaining naltrexone implant tablets; (3) dissolving the polylactic acid in the organic solvent to obtain a coating solution, and placing the coating solution in a coating pool, and then immersing the naltrexone implant tablets in the coating solution, and drying in a suspended state.Type: GrantFiled: September 21, 2018Date of Patent: December 14, 2021Assignee: Shenzhen ScienCare Medical Industries Co. Ltd.Inventors: Shugui Yin, Shiqiang Wang, Shaowei Jia, Tao Zhang, Qingzhe Liu
-
Patent number: 11197830Abstract: Solid oral dosage forms containing 325 mg of acetaminophen and 97.5 mg of ibuprofen or 500 mg of acetaminophen and 150 mg of ibuprofen, wherein the ibuprofen has a [D50] between 1 and 9 ?m, are described.Type: GrantFiled: February 27, 2019Date of Patent: December 14, 2021Inventors: Maura Murphy, Matt Callahan
-
Patent number: 11197831Abstract: A composition is described that includes lipid microcapsules and at least one dispersed active principle. A method is also described for preparing the composition. Also described, is the use of the composition in the treatment of dermatological diseases.Type: GrantFiled: May 27, 2016Date of Patent: December 14, 2021Assignee: GALDERMA RESEARCH AND DEVELOPMENTInventors: Carole Dubayle, Claire Mallard, Nicolas Atrux-Tallau
-
Patent number: 11197832Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.Type: GrantFiled: August 20, 2020Date of Patent: December 14, 2021Assignee: Cava Healthcare Inc.Inventors: Wilfred Jefferies, Reinhard Gabathuler, Raymond Andersen, Lilian Nohara, David Williams
-
Patent number: 11197833Abstract: An example blended oil composition includes a combination of Cannabidiol (CBD) oil extracted from Cannabis sativa, curcumin oil including one or more curcuminoids from turmeric rhizomes, and ginsenoside oil including one or more ginsenosides from at least one of Panax ginseng and P. quinquefolius. The Cannabis sativa comprises at least one of C. sativa, C. indica, and C. ruderalis. An example method of producing CBD oil is also disclosed.Type: GrantFiled: July 12, 2019Date of Patent: December 14, 2021Assignee: BRIGHT GREEN CORPORATIONInventor: V. Hari
-
Patent number: 11197834Abstract: In order to make available the health-promoting and healing properties of curcumin to the human or animal organism, also in combination with at least one further active substance, a solubilizate consists of or contains a content of curcumin equal to or smaller than 10 wt %, preferably equal to or smaller than 7.5 wt %, most preferably 6 wt %, and at least one emulsifier with an HLB value in a range below 18, preferably between 13 and 18, namely polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, with an average diameter of the curcumin-loaded micelles ranging from 5 nm to 40 nm, preferably from 6 nm to 20 nm, most preferably from 7 nm to 10 nm, for use in particular as a dietary supplement and/or pharmaceutical drug for treating and/or preventing diseases involving inflammation, cancer and other diseases.Type: GrantFiled: July 11, 2018Date of Patent: December 14, 2021Assignee: Aquanova AGInventor: Dariush Behnam
-
Patent number: 11197835Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.Type: GrantFiled: December 26, 2019Date of Patent: December 14, 2021Assignee: Adamas Pharma, LLCInventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
-
Patent number: 11197836Abstract: Vasoconstrictors are administered topically to provide protection against the adverse effects, e.g., alopecia, mucositis or dermatitis, induced by chemotherapy or radiotherapy. Appropriate dosages and formulations of topical vasoconstrictors are provided. Methods for the use of such compositions are also provided.Type: GrantFiled: November 6, 2015Date of Patent: December 14, 2021Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: William E. Fahl, Arnold E. Ruoho, Minesh Mehta
-
Patent number: 11197837Abstract: Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse.Type: GrantFiled: February 27, 2020Date of Patent: December 14, 2021Assignee: ACURA PHARMACEUTICALS, INC.Inventor: Ronald L. Leech, Jr.
-
Patent number: 11197838Abstract: The present invention provides a ready to use stable aqueous dosage form of norepinephrine comprising an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, one or more sulfite antioxidants and an ion chelator. The present invention also provides an infusion container filled with an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, wherein the said solution is stable for a prolonged period of time and can be terminally sterilized by autoclaving.Type: GrantFiled: August 10, 2020Date of Patent: December 14, 2021Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Samarth Kumar, Maheshkumar Parasmal Soni, Praveen Kumar Srivastava, Prashant Kane, Subhas Balaram Bhowmick
-
Patent number: 11197839Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.Type: GrantFiled: March 4, 2021Date of Patent: December 14, 2021Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 11197840Abstract: The present invention relates generally to methods for the treatment and/or prophylaxis of mental illness involving administration of 10-HDA. More particularly, methods are taught herein for the treatment and/or prophylaxis of obsessive compulsive disorder, anxiety disorder or a condition characterised by one or more symptoms of a obsessive compulsive disorder or an anxiety disorder.Type: GrantFiled: December 2, 2016Date of Patent: December 14, 2021Inventors: Wah Chin Boon, Steve Cheung
-
Patent number: 11197841Abstract: The present invention relates to compositions comprising one or more extracts and/or compounds having retinol-like activity and properties and methods of using the compositions to treat the eye.Type: GrantFiled: July 23, 2019Date of Patent: December 14, 2021Assignee: Johnson & Johnson Surgical Vision, Inc.Inventors: Wen-Hwa Ting Li, Khalid Mahmood, Ramine Parsa, Mingqi Bai, Kenneth T. Holeva
-
Patent number: 11197842Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention are in the form of a bead and comprise (i) an inert core; (ii) a first layer surrounding the inert core, wherein the first layer comprises dimethyl fumarate; and (iii) an enteric coating surrounding the first layer. Also provided are pharmaceutical compositions in the form of a bead comprising a core and an enteric coating surrounding the core, wherein the core comprises dimethyl fumarate. Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.Type: GrantFiled: November 19, 2015Date of Patent: December 14, 2021Assignee: BIOGEN MA INC.Inventors: Shyam B. Karki, Peter Zawaneh, Cheuk-Yui Leung, Kalyan Vasudevan, Yiqing Lin, Jin Xu, Andrea Trementozzi
-
Patent number: 11197843Abstract: Provided is a process for production of fucoxanthin and/or polysaccharides from microalgae and the use of purified fucoxanthin thereof in pharmaceutical, cosmetic, nutraceutical and food compositions.Type: GrantFiled: August 23, 2016Date of Patent: December 14, 2021Assignee: ALGAHEALTH (AH) LTD.Inventor: Oran Ayalon
-
Patent number: 11197844Abstract: A combination of three well-known and FDA approved compounds has been discovered to significantly suppress the proliferation of pancreatic cancer cells in clinically relevant models of pancreatic cancer. Embodiments of the invention include compositions of matter comprising a combination of agents such as metformin, simvastatin, and digoxin as well as methods of treating cancers using such agents. Illustrative methods include combining a population of pancreatic cancer cells with amounts of metformin, simvastatin, and digoxin sufficient to inhibit expression of BIRC5 protein in the population of pancreatic cancer cells, thereby inhibiting the growth of the population of pancreatic cancer cells.Type: GrantFiled: October 9, 2020Date of Patent: December 14, 2021Assignee: The Regents of the University of CaliforniaInventors: Francis C. Brunicardi, Robbi L. Sanchez
-
Patent number: 11197845Abstract: The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.Type: GrantFiled: October 10, 2019Date of Patent: December 14, 2021Assignee: SciSparc Ltd.Inventors: Ephraim Brener, Elran Haber, Ascher Shmulewitz
-
Patent number: 11197846Abstract: The present invention provides methods of treating cannabis withdrawal syndrome and other cannabis related conditions, including cannabis use disorder, in a subject, comprising administering to the subject in need thereof an effective amount of a cannabinoid or an effective amount of a cannabinoid and an effective amount of a second active agent, such as gabapentin or a gabapentin analog.Type: GrantFiled: April 29, 2021Date of Patent: December 14, 2021Assignee: Pleopharma L.L.C.Inventor: Ginger D. Constantine
-
Patent number: 11197847Abstract: Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.Type: GrantFiled: March 5, 2021Date of Patent: December 14, 2021Assignee: Tarsus Pharmaceuticals, Inc.Inventors: Bobak Robert Azamian, Douglas Michael Ackermann, Shawn D. Hickok, Joseph G. Vehige
-
Patent number: 11197848Abstract: Provided is a topical pharmaceutical gel composition of an amlodipine salt and methods for its use in the treatment of anorectal disease.Type: GrantFiled: May 29, 2019Date of Patent: December 14, 2021Inventors: László Ritter, László Hornok, Péter Mátyus, Romána Zelkó, Andrea Ujhelyi, Richárd Balázs Kárpáti, Tamás Solymosi, Hristos Glavinas
-
Patent number: 11197849Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.Type: GrantFiled: May 29, 2020Date of Patent: December 14, 2021Assignee: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata
-
Patent number: 11197850Abstract: A powder injection of a donepezil semi palmoxiric acid salt, a composition containing the same and a preparation method therefor. The powder injection contains donepezil semi palmoxiric acid salt crystals, and the average grain size of the crystals ranges from 0.5 ?m to 100 ?m.Type: GrantFiled: February 13, 2018Date of Patent: December 14, 2021Assignees: Shanghai Synergy Pharmaceutical Sciences Co., Ltd., Zhejiang Huahai Pharmaceutical Co., Ltd.Inventors: Jian Ge, Yunfei Li, Lihong Lin, Dengxue Sun, Jiamiao Wang, Yijin Wang, Zhiyun Wang
-
Patent number: 11197851Abstract: Described herein are methods of administering the non-steroidal anti-inflammatory drug norketotifen, an isomer, an isomeric mixture, a prodrug, or a pharmaceutically acceptable salt thereof for the treatment of a respiratory disorders such as COPD and asthma to human patient in need of such treatment, without exposing said patient to adverse immune-suppressive effects. Methods include treating acute and potentially life-threatening exacerbations of COPD and asthma with norketotifen.Type: GrantFiled: February 17, 2021Date of Patent: December 14, 2021Assignee: BRIDGE PHARMA INC.Inventors: A. K. Gunnar Aberg, Vincent B. Ciofalo, Kresimir Pucaj
-
Patent number: 11197852Abstract: Provided are methods for continuously administering to a subject in need of treatment a formulation comprising an immunomodulatory imide compound. In some embodiments, the method are for use in treating multiple myeloma, transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes, mantle cell lymphoma, hematologic cancers, or solid tumor cancers.Type: GrantFiled: April 21, 2020Date of Patent: December 14, 2021Assignee: Starton Therapeutics, Inc.Inventors: Marina Borovinskaya, Fotios Plakogiannis, Nisarg Modi, Tamanna Lather, Rod L. Hartwig, James C. Oliver, Yuliya Levintova
-
Patent number: 11197853Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.Type: GrantFiled: April 23, 2021Date of Patent: December 14, 2021Assignee: Aerie Pharmaceuticals, Inc.Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
-
Patent number: 11197854Abstract: The present invention relates to methods for identifying candidate therapeutics for a disease caused by a viral envelope protein. In particular, the method can include contacting a test envelope protein with the candidate and determining its activity.Type: GrantFiled: November 14, 2019Date of Patent: December 14, 2021Assignee: National Technology & Engineering Solutions of Sandia, LLCInventors: Michael S. Kent, Susan Rempe, Juan M. Vanegas
-
Patent number: 11197855Abstract: A use of of ligustrazine nitrone derivatives and a pharmaceutical composition thereof in the preparation of medicine for preventing and treating diabetic complication diseases. The ligustrazine nitrone derivatives can be prepared into various dose forms together with drug carriers.Type: GrantFiled: May 25, 2018Date of Patent: December 14, 2021Inventors: Yuqiang Wang, Yewei Sun, Lipeng Xu, Mei Jing, Zaijun Zhang, Gaoxiao Zhang, Pei Yu, Peng Yi
-
Patent number: 11197856Abstract: Embodiments of this invention provide compositions and methods for therapeutic use of diketopiperazines including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat symptoms of Autistic Disorder or Autism, as well as manufacture of medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.Type: GrantFiled: January 22, 2020Date of Patent: December 14, 2021Assignee: NEUREN PHARMACEUTICALS LIMITEDInventors: Lawrence Irwin Glass, Michael John Bickerdike, Michael Frederick Snape, Patricia Cogram
-
Patent number: 11197857Abstract: The present invention provides a combination of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The present invention also provides methods for treating cancer in a human in need thereof, the methods comprising administering to the human a combination of a Type I PRMT inhibitor and a Type II PRMT inhibitor, together with at least one of: a pharmaceutically acceptable carrier and a pharmaceutically acceptable diluent, thereby treating the cancer in the human. The present invention further provide a pharmaceutical composition comprising a therapeutically effective amount of a Type I PRMT inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of a Type II PRMT inhibitor.Type: GrantFiled: November 30, 2017Date of Patent: December 14, 2021Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Olena I. Barbash, Andy Fedoriw, Sarah Gerhart, Ryan G. Kruger, Jenny Laraio, Helai Mohammad, Shane W. Obrien, Jacob Rubin, Niyant Shah, Ping Zhang
-
Patent number: 11197858Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: January 27, 2020Date of Patent: December 14, 2021Assignee: Cardurion Pharmaceuticals, LLCInventors: Nobuyuki Matsunaga, Takashi Nakahata, Yuta Tanaka, Hiroki Takahagi, Yasufumi Miyamoto, Rei Okamoto, Takeshi Yoshikawa, Yoshito Terao, Takafumi Yukawa, Keiko Kakegawa, Yoichi Nishikawa, Terufumi Takagi, Masashi Takahashi, Mallareddy Komandla, Lily Kwok, Joanne Miura, Mark Sabat, Nicholas Scorah, Paul Tanis, John Tyhonas, Phong H. Vu, Haixia Wang, Xiaolun Wang, Junya Shirai, Tomohiro Okawa, Zenyu Shiokawa, Akito Shibuya
-
Patent number: 11197859Abstract: The disclosure provides compounds of formula (I): said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.Type: GrantFiled: August 4, 2020Date of Patent: December 14, 2021Assignee: AUTIFONY THERAPEUTICS LIMITEDInventors: Giuseppe Alvaro, Paolo Dambruoso, Simona Tommasi, Anne Decor, Charles Large, Agostino Marasco
-
Patent number: 11197860Abstract: Methods of treating Primary Biliary Cholangitis and/or Primary Sclerosing Cholangitis with baricitinib, including formulations and dose regimens. The amount of baricitinib may be administered as a 4 mg tablet or pill that includes one or more excipients. The amount of baricitinib may be administered daily or at some other frequency.Type: GrantFiled: October 10, 2019Date of Patent: December 14, 2021Assignee: Eli Lilly and CompanyInventors: Patrick L McCollam, James Michael McGill, Ana Luisa de Macedo Pinto Correia
-
Patent number: 11197861Abstract: The invention discloses methods for screening out of a BRaf inhibitor population, suitable BRaf inhibitors as candidates for clinical development of drugs for treating and/or preventing cutaneous reaction caused by treatment with EGFR inhibitor and/or PI3K inhibitors.Type: GrantFiled: January 9, 2020Date of Patent: December 14, 2021Assignee: Lutris Pharma Ltd.Inventor: Noa Shelach
-
Patent number: 11197862Abstract: Methods for reducing platinum drug-induced toxicity in a cell expressing Organic Cation Transporter 2 (OCT2), methods for reducing platinum drug-induced toxicity in a subject, methods for treating cancer, methods for increasing efficacy of platinum drug treatment in a subject, and pharmaceutical compositions are described. The described methods and compositions include an OCT2 inhibitor where the OCT2 inhibitor is buflomedil or a salt thereof, dolutegravir or a salt thereof contains an imidazole, or is miconazole or a salt thereof.Type: GrantFiled: July 15, 2016Date of Patent: December 14, 2021Assignee: XOMICS BIOPHARMA, INC.Inventors: Yong Huang, Dominique P. Bridon, Xuexiang Zhang, Chien-Ming Li
-
Patent number: 11197863Abstract: Disclosed are methods and compositions for treating pediatric embryonal tumors. The methods and compositions utilize or include an inhibitor of polo-like kinase 4 (PLK4) for treating pediatric embryonal tumors.Type: GrantFiled: August 29, 2018Date of Patent: December 14, 2021Assignee: ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGOInventors: Simone T. Sredni, Tadanori Tomita
-
Patent number: 11197864Abstract: Pharmaceutical compositions of the invention include substituted riluzole pro drugs useful for the treatment of amyotrophic lateral sclerosis (ALS) and related disorders through the release of riluzole, especially to avoid patient to patient variability in first pass, hepatic metabolism promoted by Cyp 1?2. Pro-drugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process. The invention further includes pro-drugs of riluzole useful for the treatment of disease states that can be treated with riluzole through the release of riluzole from a pro-drug agent.Type: GrantFiled: July 22, 2019Date of Patent: December 14, 2021Assignee: Biohaven Pharmaceutical Holding Company LimitedInventors: Allen B. Reitz, Garry Robert Smith
-
Patent number: 11197865Abstract: This invention provides uses for promethazine in the preparation of products to treat liver cancer and/or colon cancer and/or lung cancer. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug promethazine, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that promethazine has a new use as an anti-liver cancer and/or colon cancer and/or lung cancer medication, thus achieving a new purpose for an old drug.Type: GrantFiled: June 30, 2015Date of Patent: December 14, 2021Assignee: SHANGHAI JIAO TONG UNIVERSITYInventors: Yongyong Shi, Zhijian Song
-
Patent number: 11197866Abstract: Methods and compositions for potentiating the effect of an opioid analgesic in a patient undergoing or planning to undergo opioid analgesic therapy using a potentiating amount of iboga alkaloid or pharmaceutically acceptable salt and/or solvate thereof that does not prolong the patient's QT interval by more than about 50 milliseconds.Type: GrantFiled: May 22, 2020Date of Patent: December 14, 2021Assignee: DEMERX, INC.Inventors: Holger Weis, Emeline Maillet
-
Patent number: 11197867Abstract: A compound compound having the structure: or a pharmaceutically acceptable salt thereof, wherein X is N or CR, where R is hydrogen, deuterium, C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl, aryl, heteroaryl, aryl(C1-C6 alkyl), CN, amino, alkylamino, dialkylamino, CF3, or hydroxyl; A is selected from the group consisting of a bond, C?O, —SO2—, —(C?O)NR0—, and —(CRaRb)q—, where R0 is H or C1-C4 alkyl, and Ra and Rb are independently hydrogen, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, aryl(C1-C6 alkyl), heteroaryl, (C1-C6 alkyl)heteroaryl, etc.Type: GrantFiled: July 2, 2020Date of Patent: December 14, 2021Assignee: Pfizer Inc.Inventors: Andrew Fensome, Ariamala Gopalsamy, Brian S. Gerstenberger, Ivan Viktorovich Efremov, Zhao-Kui Wan, Betsy Pierce, Jean-Baptiste Telliez, John I. Trujillo, Liying Zhang, Li Xing, Eddine Saiah
-
Patent number: 11197868Abstract: The disclosure is directed to a method of enhancing progesterone receptor (PR) activity in a mammal, which comprises administering a composition comprising an inhibitor of FK506 binding protein 51 (FKBP51) to a mammal in need thereof, such as a pregnant human female, whereby progesterone receptor activity in the mammal is enhanced as compared to a mammal not administered the composition. The method results in an extension of the gestation period and a decreased likelihood of preterm birth and fetal growth restriction.Type: GrantFiled: February 23, 2018Date of Patent: December 14, 2021Assignee: UNIVERSITY OF SOUTH FLORIDAInventors: Charles Lockwood, Özlem Guzeloglu-Kayisli, Ümit Kayisli, Frederick Schatz
-
Patent number: 11197869Abstract: Compositions for intravenous infusion of istaroxime, or a metabolite of istaroxime, in human patients suffering from heart failure are disclosed. Likewise, methods for extended infusion of istaroxime or its metabolites in individuals with heart failure are disclosed. In particular, some methods disclosed herein include the infusion of istaroxime, or a metabolite thereof, for a period of time that is greater than six hours in order to improve cardiac relaxation without triggering arrhythmogenic events in an individual suffering from heart failure. Other methods include administration of istaroxime until certain plasma concentration thresholds of istaroxime metabolites are achieved. Also disclosed are istaroxime metabolites with selective SERCA2a activation.Type: GrantFiled: April 16, 2021Date of Patent: December 14, 2021Assignee: Windtree Therapeutics, Inc.Inventors: Giuseppe Bianchi, Patrizia Ferrari, Mara Ferrandi, Paolo Barassi
-
Patent number: 11197870Abstract: The invention relates to the treatment and reduction of fibrosis, specifically hepatic fibrosis. More specifically, embodiments of the invention provide compositions and methods useful for the treatment and inhibition of hepato-fibrotic conditions associated with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), employing the use of 3?-arachidylamido-7?,12?-dihydroxy-5?-cholan-24-oic acid (Aramchol) or a pharmaceutically acceptable salt thereof. In other embodiments, the treatment and inhibition of hepato-fibrotic conditions caused by contact with hepatotoxic chemical substances or by mechanical obstruction is contemplated.Type: GrantFiled: October 20, 2017Date of Patent: December 14, 2021Assignee: Galmed Research and Development LtdInventors: Liat Hayardeny-Nissimov, Tali Gorfine, Allen Baharaff, Jose M. Mato de la Paz
-
Patent number: 11197871Abstract: This document provides methods and materials involved in treating cardiovascular conditions such as calcific aortic valve stenosis. For example, methods and materials for using sGC agonists or a combination of sGC agonists and PDE5A inhibitors to reduce calcification of heart valves and/or vessels or to slow progression of aortic sclerosis to calcific aortic valve stenosis are provided.Type: GrantFiled: December 17, 2019Date of Patent: December 14, 2021Assignee: Mayo Foundation for Medical Education and ResearchInventors: Jordan D. Miller, Bin Zhang